Get in Touch

Raising Awareness for #GBMday July 21

The need for an improved standard of care for GBM
Key Takeaways
  • The median survival of GBM in newly diagnosed patients with the best available treatments is 20.5 months.
  • GBM is the most common and most complex brain cancer. It is also the most treatment-resistant, making it the deadliest type of brain cancer.
  • There hasn’t been a new treatment in over 20 years.

July 21, 2021 

Today, we honor the patients, their families, and their physicians, nurses and teams who have been affected by this disease. 


Scientific, academic, healthcare and research organizations around the world, including National Brain Tumor Society (NBTS) and the American Cancer Society, among others, join in shining the light on Glioblastoma (GBM).

Companies such as Kintara Therapeutics seek new horizons for the treatment of GBM. The journey to developing a novel cancer therapy for these drug-resistant tumors is underway. But there is much to be done in the clinical trials and in raising awareness for this deadly disease.

Learn more about Glioblastoma #GBMday in a video on this page by Dr. John de Groot, MD Anderson, Dr. James Perry, and Kintara Therapeutics CEO, Saiid Zarrabian.

About VAL-083

VAL-083 is a "first-in-class", small-molecule, bifunctional alkylating agent that crosses the blood-brain-barrier and has a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the NCI. Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.


ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM. Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing. SAFE

HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.

Key Takeaways
  • The median survival of GBM in newly diagnosed patients with the best available treatments is 20.5 months.
  • GBM is the most common and most complex brain cancer. It is also the most treatment-resistant, making it the deadliest type of brain cancer.
  • There hasn’t been a new treatment in over 20 years.
Media Gallery
Video Gallery
Dr. James Perry - GBM Awareness Day
View on Youtube
Related Bios
Saiid Zarrabian
President and Chief Executive Officer, Director
View Full Bio>>
Dr. John de Groot
Kintara Scientific Board Member. Professor in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center.
View Full Bio>>
James Perry, M.D., FRCPC
Kintara Advisor. Chair of the Canadian Brain Tumour Consortium; Associate Scientist, Clinical Integrative Biology in the Odette Cancer Research Program at Sunnybrook Research Institute and an Associate Professor, Department of Medicine - Division of Neurology at the University of Toronto
View Full Bio>>
Contacts
Chelli Miller
chelli@contentcarnivores.com
2199216823